Summary

The Middle East and Africa hepatitis B infection market is expected to reach USD 2.21 billion by 2031 from USD 1.47 billion in 2023, growing at a CAGR of 5.2% in the forecast period of 2024 to 2031.
Market Segmentation:
Middle East and Africa Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa)- Industry Trends and Forecast to 2031

Overview of Middle East and Africa Hepatitis B Infection Market Dynamics:

Driver

• Increasing prevalence of hepatitis B infections
Restraint

• Side effects and drug resistance

Opportunity

• Advanced research and development for clinical trials

Market Players:

The key market players operating in the Middle East and Africa hepatitis B infection market are listed below:

• Gilead Sciences, Inc.
• GSK plc
• Dynavax Technologies
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb

ページTOPに戻る

Table of Contents

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET 22
1.4 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 THERAPEUTICS LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 VENDOR SHARE ANALYSIS 37
2.11 SECONDARY SOURCES 38
2.12 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHT 44
4.1 PESTAL ANALYSIS 45
4.2 PORTER FIVE FORCES 46
5 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET: REGULATIONS 47
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 47
5.2 NORTH AMERICA REGULATORY SCENARIO 55
5.3 EUROPE REGULATORY SCENARIO 63
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 67
5.5 SOUTH AMERICA REGULATORY SCENARIO 72
6 PIPELINE ANALYSIS 77
7 EPIDEMILIOGY 88
8 MARKET OVERVIEW 90
8.1 DRIVERS 92
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS 92
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS 93
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B 94
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION 95
8.2 RESTRAINTS 96
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE 96
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION 97
8.3 OPPORTUNITY 98
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B 98
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION 99
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS 100
8.4 CHALLENGES 101
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH 101
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS 102
9 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TYPE 103
9.1 OVERVIEW 104
9.2 CHRONIC 107
9.3 ACUTE 107
10 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TREATMENT 108
10.1 OVERVIEW 109
10.2 VACCINE 112
10.2.1 HOSPITAL PHARMACIES 112
10.2.2 DRUGS STORES AND RETAIL PHARMACIES 112
10.2.3 ONLINE PHARMACIES 112
10.3 ANTIVIRAL DRUGS 113
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF) 113
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF) 113
10.3.3 ENTECAVIR 113
10.3.4 OTHERS 113
10.4 IMMUNE MODULATOR DRUGS 114
10.4.1 PEGYLATED INTERFERON 114
10.4.2 INTERFERON ALPHA 114
10.5 SURGERY 115
11 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY REGION 116
11.1 MIDDLE EAST AND AFRICA 118
11.1.1 SOUTH AFRICA 120
11.1.2 SAUDI ARABIA 122
11.1.3 EGYPT 124
11.1.4 KUWAIT 126
11.1.5 QATAR 128
11.1.6 U.A.E 130
11.1.7 OMAN 132
11.1.8 BAHRAIN 134
11.1.9 REST OF MIDDLE EAST AND AFRICA 136
12 MIDDLE EAST AND AFRICA HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE 137
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
13 SWOT ANALYSIS 138
14 COMPANY PROFILE 139
14.1 GILEAD SCIENCES, INC. 139
14.1.1 COMPANY SNAPSHOT 139
14.1.2 REVENUE ANALYSIS 139
14.1.3 COMPANY SHARE ANALYSIS 140
14.1.4 PRODUCT PORTFOLIO 140
14.1.5 RECENT DEVELOPMENT 140
14.2 GLAXOSMITHKLINE PLC 142
14.2.1 COMPANY SNAPSHOT 142
14.2.2 REVENUE ANALYSIS 142
14.2.3 COMPANY SHARE ANALYSIS 143
14.2.4 PRODUCT PORTFOLIO 143
14.2.5 RECENT DEVELOPMENT 143
14.3 DYNAVAX TECHNOLOGIES CORPORATION 145
14.3.1 COMPANY SNAPSHOT 145
14.3.2 REVENUE ANALYSIS 145
14.3.3 COMPANY SHARE ANALYSIS 146
14.3.4 PRODUCT PORTFOLIO 146
14.3.5 RECENT DEVELOPMENTS 146
14.4 F. HOFFMAN-LA ROCHE LTD. 148
14.4.1 COMPANY SNAPSHOT 148
14.4.2 REVENUE ANALYSIS 148
14.4.3 COMPANY SHARE ANALYSIS 149
14.4.4 PRODUCT PORTFOLIO 149
14.4.5 RECENT DEVELOPMENTS 149
14.5 BRISTOL-MYERS SQUIBB COMPANY 150
14.5.1 COMPANY SNAPSHOT 150
14.5.2 REVENUE ANALYSIS 150
14.5.3 COMPANY SHARE ANALYSIS 151
14.5.4 PRODUCT PORTFOLIO 151
14.5.5 RECENT DEVELOPMENTS 151
14.6 ARROWHEAD PHARMACEUTICALS, INC. 152
14.6.1 COMPANY SNAPSHOT 152
14.6.2 REVENUE ANALYSIS 152
14.6.3 PRODUCT PORTFOLIO 153
14.6.4 RECENT DEVELOPMENTS 153
14.7 ARBUTUS BIOPHARMA 154
14.7.1 COMPANY SNAPSHOT 154
14.7.2 REVENUE ANALYSIS 154
14.7.3 PRODUCT PORTFOLIO 155
14.7.4 RECENT UPDATES 155
14.8 AUROBINDO PHARMA 156
14.8.1 COMPANY SNAPSHOT 156
14.8.2 REVENUE ANALYSIS 156
14.8.3 PRODUCT PORTFOLIO 157
14.8.4 RECENT UPDATES 157
14.9 LUPIN PHARMACEUTICALS, INC. 158
14.9.1 COMPANY SNAPSHOT 158
14.9.2 PRODUCT PORTFOLIO 158
14.9.3 RECENT UPDATES 159
14.10 MERCK & CO., INC., 160
14.10.1 COMPANY SNAPSHOT 160
14.10.2 REVENUE ANALYSIS 160
14.10.3 PRODUCT PORTFOLIO 161
14.10.4 RECENT DEVELOPMENTS 161
14.11 NOVARTIS AG 162
14.11.1 COMPANY SNAPSHOT 162
14.11.2 REVENUE 162
14.11.3 PRODUCT PORTFOLIO 163
14.11.4 RECENT DEVELOPMENT 163
14.12 TEVA PHARMACEUTICAL INDUSTRIES 164
14.12.1 COMPANY SNAPSHOT 164
14.12.2 PRODUCT PORTFOLIO 164
14.12.3 RECENT DEVELOPMENTS 164
14.13 ZYDUS PHARMACEUTICALS, INC. 165
14.13.1 COMPANY SNAPSHOT 165
14.13.2 PRODUCT PORTFOLIO 165
14.13.3 REVENUE 166
14.13.4 RECENT DEVELOPMENT 166
15 QUESTIONNAIRE 167
16 RELATED REPORTS 169